Handelsbanken Fonder’s Nurix Therapeutics NRIX Stock Holding History

Handelsbanken Fonder’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.4M	Buy	633,000 +86,000	+16%	+$1.46M	0.04%	319
2026 Q1	$8.48M	Hold	547,000	–	–	0.03%	393
2025 Q4	$10.4M	Buy	547,000 +27,000	+5%	+$388K	0.03%	382
2025 Q3	$4.8M	Buy	520,000 +240,000	+86%	+$2.49M	0.02%	482
2025 Q2	$3.19M	Buy	+280,000	New	+$3.03M	0.01%	515
2022 Q1	–	Sell	-7,600	Closed	-$220K	–	1718
2021 Q4	$220K	Buy	+7,600	New	+$230K	﹤0.01%	1685

Other funds holding NRIX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

WFA

WestHill Financial Advisors San Rafael, California $587M AUM 20.13% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

VIG

Vienna Insurance Group Warsaw, Poland $381M AUM 105.39% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder's NRIX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Nurix Therapeutics (NRIX) stake by 16% in Q2 2026, buying an estimated $1.46M and bringing the position to 633,000 shares worth $15.4M. The position accounts for 0.04% of the portfolio, ranked #319.

Handelsbanken Fonder first reported a position in NRIX in Q4 2021 and has held it in 6 quarters since. 36 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Handelsbanken Fonder held 633,000 shares of Nurix Therapeutics worth $15.4M as of Q2 2026.
Handelsbanken Fonder bought 86,000 Nurix Therapeutics shares in Q2 2026, an estimated $1.46M.
Nurix Therapeutics made up 0.04% of Handelsbanken Fonder's portfolio in Q2 2026, its #319 holding.
Handelsbanken Fonder first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 6 quarters since.
36 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.